CC
REGN icon

Centiva Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Centiva Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-407,100
Closed -$314M – 1951
2025
Q4 		$314M Buy
407,100
+7,100
+2% +$4.82M 2.56% 8
2025
Q3 		$225M Buy
400,000
+355,200
+793% +$201M 2.15% 8
2025
Q2 		$23.5M Buy
+44,800
New +$25M 0.38% 37
2025
Q1 		– Sell
-600
Closed -$427K – 2034
2024
Q4 		$427K Hold
600
– – 0.01% 915
2024
Q3 		$631K Buy
+600
New +$668K 0.01% 1088
2024
Q2 		– Sell
-3,600
Closed -$3.46M – 2432
2024
Q1 		$3.46M Buy
3,600
+1,100
+44% +$1.05M 0.08% 176
2023
Q4 		$2.2M Sell
2,500
-2,700
-52% -$2.22M 0.05% 329
2023
Q3 		$4.28M Sell
5,200
-1,600
-24% -$1.26M 0.09% 189
2023
Q2 		$4.89M Sell
6,800
-1,000
-13% -$771K 0.11% 185
2023
Q1 		$6.41M Buy
7,800
+3,300
+73% +$2.49M 0.16% 131
2022
Q4 		$3.25M Sell
4,500
-5,000
-53% -$3.69M 0.09% 226
2022
Q3 		$6.54M Buy
9,500
+2,500
+36% +$1.57M 0.12% 115
2022
Q2 		$4.14M Sell
7,000
-1,000
-13% -$650K 0.1% 183
2022
Q1 		$5.59M Buy
8,000
+6,900
+627% +$4.37M 0.11% 146
2021
Q4 		$695K Buy
+1,100
New +$676K 0.01% 713
2019
Q2 		– Sell
-6,400
Closed -$2.63M – 498
2019
Q1 		$2.63M Buy
6,400
+3,800
+146% +$1.56M 0.18% 93
2018
Q4 		$971K Buy
+2,600
New +$952K 0.08% 144

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Centiva Capital's REGN Position: Q1 2026 in Review

Centiva Capital opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 14,610 shares worth $11.3M. The stake represents 0.08% of the portfolio and ranks #164 among its holdings. This is a return to the name: Centiva Capital previously reported a position in REGN as recently as Q2 2025.

Centiva Capital first reported a position in REGN in Q4 2018 and has held it in 18 quarters since. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Centiva Capital held 14,610 shares of Regeneron Pharmaceuticals worth $11.3M as of Q1 2026.
  • Regeneron Pharmaceuticals was a new Centiva Capital position in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.08% of Centiva Capital's portfolio in Q1 2026, its #164 holding.
  • Centiva Capital first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 18 quarters since.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Centiva Capital's 13F filing for Q1 2026, filed 14 May 2026.